加拿大卫生政策研究所 (CHPI) 首席研究员：Yanick Labrie
https://canadianhealthpolicy.com/research-centres/centre-for-healthcare-economics-analytics-and-literacy-heal/
首席研究员：Yanick Labrie， 一位居住在蒙特利尔的卫生经济学家和公共政策顾问
医疗经济、分析与素养中心 (HEAL)
HEAL 的使命是提高加拿大公众对医疗经济和公共政策的素养。HEAL 由慈善基金会提供的独立研究经费资助。HEAL 的研究遵循以下原则：
医疗保健支出是对人力资本的投资，其产生的社会效益远大于许多其他稀缺资源的利用方式。
创新技术的开发和应用对于提高医疗保健生产力和有效最大化患者净健康效益至关重要。
受托责任和资源的稀缺性要求政策制定者优先考虑患者的健康结果和纳税人的财政可持续性，并考虑公共医疗预算拨款的机会成本。
公共医疗干预需要有证据证明政府能够在市场失灵的情况下取得成功。公共与私人资助/生产医疗产品、服务和保险的优劣可以通过实证观察来评估。
人们拥有保护和改善自身健康的基本权利。阻碍人们私下获取医疗产品、服务和保险的政策违背了自我保护的初衷。
首席研究员：Yanick Labrie，理学硕士，文学学士，经济学家
Yanick Labrie 是一位居住在蒙特利尔的卫生经济学家和公共政策顾问。他拥有康考迪亚大学经济学学士学位和蒙特利尔大学经济学硕士学位。Labrie 先生在卫生政策领域的职业生涯超过十五年。他曾在蒙特利尔经济研究所、大学间组织研究与分析中心 (CIRANO) 担任经济学家，并曾担任蒙特利尔高等商学院应用经济学院的讲师。他撰写或合作撰写了 40 多篇与医疗保健和药品政策相关的研究论文和研究报告。他的许多文章发表在《环球邮报》、《国家邮报》、《渥太华公民报》、《蒙特利尔公报》、《新闻报》和《责任报》等报刊上。他经常受邀参加会议和辩论，并在媒体上评论经济事务。
HEAL 研究主题：
卫生系统绩效、政府医疗支出的可持续性、医疗保健中的政府与市场、医疗保险设计的经济学原理、医疗创新经济学、疾病的经济负担、医疗保健生产力困境、医疗保健的经济价值、健康的社会决定因素、影响价格的公共政策、卫生专业人员及医疗产品和服务的供求关系、公共医疗资源竞争使用的机会成本、经济激励、竞争、利润动机等。
Brett Skinner 布雷特·斯金纳 | 博士、文学硕士、文学学士 | CHPI 首席执行官 | CHP 期刊编辑
2015 年，被诊断出患有一种非典型早发性帕金森病，对现有药物无反应。
布雷特·斯金纳是 CHPI 的创始人兼首席执行官，也是《加拿大卫生政策》期刊的主编（2012 年至今）。他是一位学术型企业家、卫生政策专家，著有两部著作、100 多篇重要政策论文和 100 多篇社论。
斯金纳博士拥有西部大学博士学位，曾在该校卫生科学学院和政治学系任教。他在政策研究和倡导方面拥有丰富的领导经验，曾担任加拿大创新药物协会卫生与经济政策执行主任（2013-2017 年），以及弗雷泽研究所首席执行官（2010-2012 年）和卫生政策主任（2004-2012 年）。
Skinner 博士是 CHPI 创新药物获取研究项目的主席，该项目是一项年度政策研究，旨在识别获取新型专利药物的障碍，开发实证指标并提出解决方案。
他积极倡导促进创新医疗发展和获取的政策。2015 年，他被诊断出患有一种非典型早发性帕金森病，对现有药物无反应。他对影响未来医疗创新的政府决策既有学术兴趣，也有个人健康方面的考量。
Brett Skinner | PhD MA BA | CEO CHPI | Editor CHP Journal
Brett Skinner is the Founder and CEO of CHPI and Editor-in-Chief of Canadian Health Policy journal (2012-present). He is an academic entrepreneur, health policy expert, and author of 2 books, over 100 major policy papers, and over 100 opinion editorials.
Dr. Skinner has a PhD from Western University, where he has lectured in the Faculty of Health Sciences and the Department of Political Science. His extensive leadership experience in policy research and advocacy includes Executive Director of Health and Economic Policy at Innovative Medicines Canada (2013-2017), and CEO (2010-2012) and Director of Health Policy (2004-2012) at Fraser Institute.
Dr. Skinner chairs CHPI’s Access to Innovative Medicines research program, an annual program of policy research designed to identify barriers to accessing new patented medicines, develop empirical metrics, and propose options for solutions.
He is a passionate advocate for policies that promote the development of, and access to innovative medical treatments. In 2015, he was diagnosed with an atypical form of early onset Parkinson’s disease that is non-responsive to existing medications. He has both an academic interest and a personal health stake in government choices affecting future medical innovation.
Laurie Skinner | RN BHA | 执行编辑
Laurie Skinner 是加拿大卫生政策研究所 (CHPI) 的执行编辑。Laurie 拥有泰德·罗杰斯管理学院卫生管理学士学位，并就读于多伦多瑞尔森大学卫生服务管理专业。她是一名注册护士 (R.N.)，拥有温莎圣克莱尔学院的健康科学文凭，并在温莎大学学习过工商管理和社会科学。她曾在温莎地区医院大都会院区的产妇/新生儿病房和特护病房以及多伦多桑尼布鲁克女子学院医院的联合护理病房从事临床护理工作。
Laurie 还曾担任安大略省医学协会 (OMA) 的项目协调员、HealthForceOntario MRA 的医师助理招聘顾问，以及安大略省实习医生和住院医生专业协会 (PAIRO) / HFOJobs (HealthForceOntario) 的护理招聘协调员。
Laurie 曾为安大略省 16 家医院的人力资源专业人士、安大略省卫生和长期护理部的工作人员、包括安大略省医院协会在内的多个医疗保健组织的代表以及多伦多大学、西安大略大学、约克大学和塞内卡学院的护理专业学生进行过各种演讲。
Sarah Lussier-Hoskyn | 文学硕士、文学学士 | 经济学家
Sarah Lussier Hoskyn 在滑铁卢大学获得经济学硕士学位，并在麦吉尔大学获得经济学学士学位。她在加拿大药品政策研究领域拥有 15 年经验，研究领域涵盖加拿大的监管和报销绩效、私人药品计划药品成本趋势、定价政策（PMPRB）、研发投资价值和临床试验。2015 年至 2020 年，Sarah 担任加拿大创新药物协会 (Innovative Medicines Canada) 的研究总监兼监管事务和市场准入高级分析师。2006 年至 2015 年，Sarah 担任 Brogan Inc.（又名 IMS Brogan、IMS Health、Quintiles IMS 和 IQVIA）的项目经理、高级价格监管顾问和健康经济顾问。
Sarah 与他人合作撰写了两篇关于药品政策主题的论文，发表在同行评审期刊《药理学前沿》(Frontiers in Pharmacology) 上。 Sarah 目前的工作重点是帮助雇主了解工作场所的慢性病负担，诊断潜在病因，并寻找创新的循证解决方案，以补充其现有的福利和健康计划，从而改善工作场所的健康和生产力，并最终降低成本。这转化为她对健康和保健福利政策的研究兴趣，这些政策旨在减轻疾病负担和由此产生的医疗保健成本，并提高整体劳动生产率和经济竞争力。
Sarah Lussier-Hoskyn | MA BA | Economist
Sarah Lussier Hoskyn earned her Master’s degree in Economics at the University of Waterloo and a Bachelor degree in Economics at McGill University. She has 15 years of experience in pharmaceutical policy research in such areas as Canada’s regulatory and reimbursement performance, private drug plan drug costs trends, pricing policy (PMPRB), the value of R&D investments and clinical trials. From 2015 to 2020, Sarah was Director of Research, and Senior Analyst Regulatory Affairs and Market Access, Innovative Medicines Canada. From 2006 to 2015, Sarah was Engagement Manager, Senior Price Regulation Consultant, and Health Economist Consultant at Brogan Inc. (aka. IMS Brogan, IMS Health, Quintiles IMS, and IQVIA).
Sarah co-authored 2 papers on pharmaceutical policy topics that were published in the peer-reviewed journal Frontiers in Pharmacology. Sarah’s current focus is to help employers figure out their chronic disease burden in their workplace, diagnose the underlying causes, and find innovative evidence-based solutions to complement their existing benefits and wellness plans to improve their workplace health and productivity, and ultimately to reduce costs. This translates into a research interest in policies for health and wellness benefits that reduce the disease burden and resulting health care costs, and improve overall labour productivity and economic competitiveness.
Canadian Health Policy Institute (CHPI)
https://canadianhealthpolicy.com/research-centres/centre-for-healthcare-economics-analytics-and-literacy-heal/
Centre for Healthcare Economics, Analytics, and Literacy (HEAL)
HEAL’s mission is to improve public literacy regarding healthcare economics and public policy in Canada. HEAL is funded by independent research grants from charitable foundations. HEAL research is aligned with the following principles:
- Healthcare spending is an investment in human capital, producing greater societal benefits than many alternative uses of scarce resources.
- Development and adoption of innovative technologies is vital to increasing healthcare productivity and efficient maximization of net health benefits for patients.
- Fiduciary responsibilities and the scarcity of resources require policymakers to prioritize patient health outcomes and fiscal sustainability for taxpayers, and to consider the opportunity cost of allocations from public healthcare budgets.
- Public intervention in healthcare requires evidence that government can succeed where markets have failed. The merits of public versus private funding/production of medical goods, services and insurance can be evaluated through empirical observation.
- People have a fundamental right to protect and improve their health. Policies that hinder people from privately obtaining medical goods, services, and insurance are contrary to self-preservation.
LEAD RESEARCHER: Yanick Labrie, MSc BA, Economist
Yanick Labrie is a health economist and public policy consultant living in Montreal. He holds a BA Economics, Concordia University and MSc Economics, Université de Montréal. Mr. Labrie’s career in health policy spans more than fifteen years. He has worked as an economist at the Montreal Economic Institute, the Center for Interuniversity Research and Analysis on Organizations (CIRANO) and was a lecturer at HEC Montréal’s Institute of Applied Economics. He authored or co-authored more than 40 research papers and studies related to healthcare and pharmaceutical policies. Many of his articles have appeared in The Globe and Mail, The National Post, The Ottawa Citizen, The Montreal Gazette, La Presse and Le Devoir, among other newspapers. He is frequently invited to participate in conferences and debates, and to comment on economic affairs in the media.
HEAL research topics:
Health system performance, sustainability of government expenditure on healthcare, governments and markets in healthcare, economic principles of medical insurance design, economics of medical innovation, economic burden of illness, healthcare productivity dilemma, economic value of healthcare, social determinants of health, public policies affecting prices, supply and demand regarding health professionals and medical goods and services, opportunity cost of competing uses of public health care resources, economic incentives, competition, the profit motive, etc.
